Abcellera Biologics Inc ABCL

$11.13 -1.15 (-9.36%)

Valuation

Market cap
3,765,183,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
4,131,800
Avg volume
4,469,752
Day's range
$10.76 – $11.88
Shares out
306,611,000
Stochastic %K
12%
Beta
1.59
Analysts
Strong Buy
Price target
$17.17

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Stocktradesmoon Nov 6, 12:51 PM
$ABCL $MRNA $REGN $LLY $SLS $ABCL Part 1/2 this might be my last normal tweet before biotech goes vertical i’m not a whistleblower. I don’t work at Lilly, Novo or any of the big labs but there is a massive shift happening in human biology right now. it’s sitting in press releases and almost nobody reads them the last 6 months alone: - a once-daily pill roughly doubled median survival in metastatic pancreatic cancer (13.2 vs 6.6 months) Continue… Part 2 Follows 👇🏻CLICK Sub-POST‼️
1 replies
Stocktradesmoon Nov 6, 12:45 PM
$ABCL ❤️ $MRNA $SLS $LLY $REGN ABcellera 🔥 🔥 UPGRADES!!! BOOM!! Price targets (👀New Upgrade JEFFERIES $21🎯 🔵 Truist Securities — $30 🔴 JonesTrading — $25 🟡 UBS — $18 🟢 JPMorgan — $17 🟣 BMO Capital — $15 🟠 Goldman Sachs — $13 🩵 Cantor Fitzgerald — $12 🩷 Stifel — $9 ABCL — ANALYST PRICE TARGETS (USD) Truist Securities: $12 → $30 (+150%) JonesTrading: $13 → $25 (+92.3%) UBS: $18 (New Coverage) JPMorgan: $17 (New Coverage) BMO Capital: $15 Goldman Sachs: $13 (New Coverage) Cantor Fitzgerald: $11 → $12 (+9.1%) Stifel: $8 → $9 (+12.5%) 👀🚨🔥JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on AbCellera Biologics and set a price target of $25.00. She’s actually a very accurate Analyst!! So this is a STRONG SIGNAL $25’ssss!
0 replies
Stocktradesmoon Nov 6, 12:40 PM
$ABCL $REGN $MRNA $SLS $PFE 🔥Jp Morgan, UBS, and Goldman target prices for $ABCL: $18, $17, and $13 and Jefferies at $21. 🙌 Today you have the chance to buy at $11.X Close to the same price at which Andrew Booth bought 37,200 shares, Michael Hayden bought over $1M worth, and John Montalbano another $110K 🤓 💡When the CFO and several board members buy over $1.5M out of their own pockets after learning about some spectacular clinical data, and the market gives you the chance to fish in the same river... You guys decide for yourselves...
0 replies
Stocktradesmoon Nov 6, 12:34 PM
$ABCL ❤️ $MRNA $REGN $SLS $PFE One subcutaneous shot. Four weeks of fewer and milder hot flashes. No serious adverse events. The approved drugs in this class are daily pills. ABCL635 competes on the dosing schedule as much as on effect size, and patients feel that difference every single morning. $ABCL
0 replies
Stocktradesmoon Nov 6, 12:30 PM
$ABCL ❤️ $REGN $MRNA $SLS $PFE $ABCL Jazz Pharma reported yesterday, 11/ 2, 2026, And here’s the important part for ABCL: Jazz’s 11/ 2 filing also confirms the AbCellera collaboration: $56 million in upfront payments for the 1st 2 programs and potential milestone payments of up to $792M per program+ royalties!
0 replies
Stocktradesmoon Nov 6, 12:17 PM
$ABCL $REGN $PFE $SLS $INOD ABcellera 🔥!!! 👀🚀 👀🚨 4 MAJOR Catalyst Events All HAPPENING in a few days!! 👀👏🚀 — November could be more important than the recent share price rally. Here’s exactly what I’m watching. November 9: Q3 earnings and pipeline update. November 11: Stifel Healthcare Conference. November 16: Jefferies Global Healthcare Conference in London. AND… We got MORE NEWS 🗞️ YESTERDAY After-Hours!! + ABcellera to Present @ the UBS GLOBAL BIOPHARMA Conference on November 17, 2026!!
1 replies
Odoji Nov 6, 11:36 AM
$ABCL 💉
0 replies
Stocktradesmoon Nov 6, 11:20 AM
$ABCL $INOD $PFE $REGN $SLS
2 replies